Nanobiotix Files 6-K with H1 2025 Financials
Ticker: NBTX · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1760854
Sentiment: neutral
Topics: financial-report, pharmaceutical, sec-filing
TL;DR
Nanobiotix dropped its Q2 2025 financials - check the net loss and capital reserves.
AI Summary
Nanobiotix S.A. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first six months of 2025 and the full year 2024, detailing items such as net loss for the period, issued capital, share premium, and accumulated other comprehensive income. The company is based in Paris, France, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with an update on Nanobiotix's financial performance and position as of mid-2025, crucial for assessing the company's ongoing operations and strategic direction.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Nanobiotix faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial filings.
Key Numbers
- 2025 Q2 — Reporting Period (Financials cover the second quarter of 2025.)
- 2024-12-31 — Previous Year End (Comparative financial data from the end of 2024 is included.)
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the report
- 0001628280-25-043232 (other) — Accession number for the filing
- 20250630 (date) — Reporting period end date
- 20250930 (date) — Filing date
- Paris, France (location) — Company's business address
FAQ
What was Nanobiotix's net loss for the period ending June 30, 2025?
The filing indicates 'nbx:NetLossForThePeriodMember' for the period 2025-01-01 to 2025-06-30, but the specific dollar amount is not provided in the extracted text.
What is the company's fiscal year end?
Nanobiotix S.A.'s fiscal year ends on December 31 (1231).
What is the SIC code for Nanobiotix S.A.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was this 6-K filing submitted to the SEC?
The filing was submitted on September 30, 2025.
What financial elements are reported for both 2024 and 2025 periods?
The filing references 'ifrs-full:IssuedCapitalMember', 'ifrs-full:SharePremiumMember', 'ifrs-full:AccumulatedOtherComprehensiveIncomeMember', and 'ifrs-full:CapitalReserveMember' for both 2024-12-31 and the period ending 2025-06-30.
Filing Stats: 4,355 words · 17 min read · ~15 pages · Grade level 15.2 · Accepted 2025-09-30 16:19:43
Filing Documents
- nbx-20250630.htm (6-K) — 1703KB
- 0001628280-25-043232.txt ( ) — 11149KB
- nbx-20250630.xsd (EX-101.SCH) — 114KB
- nbx-20250630_cal.xml (EX-101.CAL) — 100KB
- nbx-20250630_def.xml (EX-101.DEF) — 405KB
- nbx-20250630_lab.xml (EX-101.LAB) — 775KB
- nbx-20250630_pre.xml (EX-101.PRE) — 625KB
- nbx-20250630_htm.xml (XML) — 2232KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NANOBIOTIX S.A. /s/ LAURENT LEVY By: Laurent Levy, Ph.D. Title: Chairman of the Executive Board Date: September 30, 2025 EXHIBIT 99.1 NANOBIOTIX HALF-YEAR FINANCIAL REPORT From January 1, 2025 to June 30, 2025 September 30, 2025 EXHIBIT 99.1 TABLE OF CONTENTS Page I. Interim activity report 3 Company information 3 Significant events during the six-month period ended June 30, 2025 3 Company activity over the six-month ended June 30, 2025 5 Future prospects 6 Main risks and uncertainties for the remaining six months 7 Key transactions with related parties 7 Liquidity and capital resources 8 II. Unaudited interim condensed consolidated financial statements F- 10 Unaudited interim condensed statements of consolidated financial position F- 1 Unaudited interim condensed statements of consolidated operations F- 2 Unaudited interim condensed statements of consolidated comprehensive loss F- 3 Unaudited interim condensed statements of consolidated changes in shareholders' equity F- 4 Unaudited interim condensed statements of consolidated cash flows F- 5 Notes to the unaudited interim condensed consolidated financial statements F- 6 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This interim and semi-annual report (the "Report") contains "forward-looking statements" within the meaning of applicable federal securities laws, including the Private Securities Litigation Reform Act of 1995. All statements other than present and historical facts and conditions contained in this Report, including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this Report, the words "consider